Presentations

      A New Fluorescence Based Method for the Characterization of In Vitro Aerosol Exposure Systems

      Steiner, S.; Majeed, S.; Kleinhans, S.; Nordlund, M.; Frentzel, S.; Mathis, C.; Hoeng, J.

      Conference date
      Apr 4, 2016
      Conference name
      IIVS Exposure-Dosimetry workshop
      Link to more information
      Topic
      Summary

      The Institute for In Vitro Sciences (IIVS) brought together stakeholders from industry, government and academia to discuss considerations for exposure and dosimetry for non-animal testing during its 2.5-day workshop, “In Vitro Exposure Systems and Dosimetry Assessment Tools for Inhaled Tobacco Products”, held April 4-6, 2016 in Bethesda, MD. Uniquely focused on in vitro testing, the workshop is the only known event of its kind.Attendees, including toxicologists from industry, the FDA Center for Tobacco Products, the National Center for Toxicological Research and the US Environmental Protection Agency, heard presentations, attended poster sessions and breakout groups to gain a deeper understanding of the issues involving exposure and dosimetry of aerosols to cells and tissues in culture. Topics included the current status of in vitro to in vivo correlations, whole tobacco smoke and E-cigarette aerosol/vapor constituents, in vitro exposure systems, dosimetry approaches, the exposure microenvironment, and promising technologies that may advance science in these areas.To date, much of the research and testing in respiratory and inhalation toxicology have focused on the use of animal models. With the development of new technologies, such as reconstructed human airway tissues, researchers are turning their attention to in vitro assessments. 

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.